The Director,
DHA will identify each high-value medication that is covered under
the Pilot. An Interim Final Rule published in the
Federal
Register on September 29, 2017, made a number of improvements in
the TRICARE Program based on provisions of the NDAA for FY 2017,
including Section 701(h). That Rule, in
32 CFR 199.17(f)(4), authorizes the Director
to use the Department of Defense (DoD) Pharmacy and Therapeutics
Committee process under
32 CFR 199.21 to
determine which high-value medications would improve health outcomes
and identify those medications and applicable copayments made available
under this Pilot. A list of the selected high-value medications
and applicable copayments will be maintained by DHA and made available
to beneficiaries and providers through the following website:
https://health.mil/formulary.